Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients

American Journal of Cardiology

Volumn 90, Issue 9, 2002, Pages 942-946

  Bays, Harold E ^a   Stein, Evan A ^b   Shah, Arvind K ^c   Maccubbin, Darbie L ^c   Mitchel, Yale B ^c   Mercuri, Michele ^c  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b Metabolic and Atherosclerosis Research Center   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SERUM AMYLOID A; SIMVASTATIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; INTERLEUKIN-6; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SERUM AMYLOID A PROTEIN; SIMVASTATIN; STATISTICS; TREATMENT OUTCOME; TRIGLYCERIDES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0036829672     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02658-9     Document Type: Article

References (30)

1. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979.
2. Koenig W., Sund M., Frohlich M., Fischer H.-G., Löwel H., Döring A., Hutchinson W., Pepys M.B. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 99:1999;237-242.
3. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 342:2000;836-843.
4. Haverkate F., Thompson S.G., Pyke S.D.M., Gallimore J.R., Pepys M.B., for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group . Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 349:1997;462-466.
5. Pietilä K.O., Harmoinen A.P., Jokiniitty J., Pasternack A.I. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic therapy. Eur Heart J. 17:1996;1345-1349.
6. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.J., for the West of Scotland Coronary Prevention Study Group . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
7. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendörfer A., Stein E.A., Kruyer W., Gotto A.M. Jr, for the AFCAPS/TexCAPS Research Group . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.
8. Scandinavian Simvastatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
9. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C.-C., Davis B.R., Braunwald E., for the Cholesterol and Recurrent Events Trial Investigators . The effect of pravastatin on coronary events after myocardial infarction in participants with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
10. Hunt D., Young P., Simes J., Hague W., Mann S., Owensby D., Lane G., Tonkin A. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients results of the LIPID trial . Ann Intern Med. 134:2001;931-940.
11. Rosenson R.S., Tangney C.C., Casey L.C. Inhibition of proinflammatory cytokine production by pravastastin. Lancet. 353:1999;983-984.
12. Ferro D., Parrotto S., Basili S., Alessandri C., Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol. 36:2000;427-431.
13. März W., Wieland H. HMG-CoA reductase inhibition antiinflammatory effects beyond lipid lowering? Herz. 25:2000;117-125.
14. Rosenson R.S., Tangney C.C. Antiatherothrombic properties of statins implications for cardiovascular event reduction . JAMA. 279:1998;1643-1650.
15. Koh K.K. Effects of statins on vascular wall vasomotor function, inflammation, and plaque stability . Cardiovasc Res. 47:2000;648-657.
16. Stein E., Plotkin D., Bays H., Davidson M., Dujovne C., Korenman S., Stepanavage M., Mercuri M. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol. 86:2000;406-411.
17. Isaacsohn J, Hunninghake D, Schrott H, Dujovne CA, Knopp R, Weiss SR, Bays H, Crouse JR, Davidson MH, Keilson LM, et al. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol, in press.
18. Steiner P., Freidel J., Bremmer W., Stein E. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the clinics' methodology. J Clin Chem. 19:1981;850-851.
19. Warnick G., Albers J. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res. 19:1978;65-76.
20. Program LRC. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. Washington, DC: US Department of Health Education and Welfare. NIH Publication No. 75-628, 1982.
21. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., Flaker G.C., Braunwald E., for the Cholesterol, and Recurrent Events (CARE) Investigators . Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844.
22. Albert M.A., Danielson E., Rifai N., Ridker P.M., for the PRINCE Investigators . Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE) a randomized trial and cohort study . JAMA. 286:2001;64-70.
23. Wu T., Dorn J.P., Donahue R.P., Sempos C.T., Trevisan M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin. Am J Epidemiol. 155:2002;65-71.
24. Lemieux I., Pascot A., Prud'homme D., Almeras N., Bogaty P., Nadeau A., Bergeron J., Despres J.P. Elevated C-reactive protein another component of the atherothrombotic profile of abdominal obesity . Arterioscler Thromb Vasc Biol. 21:2001;961-967.
25. Ridker P.M., Rifai N., Clearfield N., Downs J.R., Weiss S.E., Miles J.S., Gotto A.M. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 344:2001;1959-1965.
26. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 103:2001;1191-1193.
27. Strandberg T.E., Vanhanen H., Tikkanen M.J. Associations between change in C-reactive protein and serum lipids during statin treatment. Ann Med. 32:2000;579-583.
28. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of interleukin 6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 101:2000;1767-1772.
29. Liuzzo G., Biasucci L.M., Gallimore J.R., Grillo R.L., Rebuzzi A.G., Pepys M.B., Maseri A. The prognostic value of C-reactive protein and serum amyloid A in severe unstable angina. N Engl J Med. 331:1994;417-424.
30. Hackman A., Abe Y., Insull W., Pownall H., Smith L., Dunn K., Gotto A.M., Ballantyne C.M. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation. 93:1996;1334-1338.